title: p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.
abstract: Chromosomal translocation (8;21) is present in 10% to 15% of patients with acute myeloid leukemia. Expression of the AML1-ETO (AE) fusion protein alone is not sufficient to induce leukemia, but the nature of the additional genetic alterations is unknown. It is unclear whether AE facilitates acquisition of these cooperating events. We show that AE down-regulates genes involved in multiple DNA repair pathways, potentially through a mechanism involving direct binding at promoter elements, and increases the mutation frequency in vivo. AE cells display increased DNA damage in vitro and have an activated p53 pathway. This results in increased basal apoptosis and enhanced sensitivity to DNA damaging agents. Intriguingly, microarray data indicate that t(8;21) patient samples exhibit decreased expression of DNA repair genes and increased expression of p53 response genes compared with other acute myeloid leukemia (AML) patient samples. Inhibition of the p53 pathway by RNAi increases the resistance of AE cells to DNA damage. We thus speculate that AML1-ETO may facilitate accumulation of genetic alterations by suppressing endogenous DNA repair. It is possible that the superior outcome of t(8;21) patients is partly due to an activated p53 pathway, and that loss of the p53 response pathway is associated with disease progression.
authors.affiliation: Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, OH 45226, USA.
authors.forename: Ondrej
authors.initials: O
authors.lastname: Krejci
authors.forename: Mark
authors.initials: M
authors.lastname: Wunderlich
authors.forename: Hartmut
authors.initials: H
authors.lastname: Geiger
authors.forename: Fu-Sheng
authors.initials: FS
authors.lastname: Chou
authors.forename: David
authors.initials: D
authors.lastname: Schleimer
authors.forename: Michael
authors.initials: M
authors.lastname: Jansen
authors.forename: Paul R
authors.initials: PR
authors.lastname: Andreassen
authors.forename: James C
authors.initials: JC
authors.lastname: Mulloy
mesh_terms: D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood; D001483:Base Sequence; D016923:Cell Death / Q000502:physiology*; D002455:Cell Division; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics* / Q000378:metabolism; D004249:DNA Damage; D004260:DNA Repair / Q000235:genetics; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D007231:Infant, Newborn; D008969:Molecular Sequence Data; D020411:Oligonucleotide Array Sequence Analysis; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000378:metabolism; D000075142:RUNX1 Translocation Partner 1 Protein; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000502:physiology*
chemical_list: C107844:AML1-ETO fusion protein, human; D015703:Antigens, CD; D018952:Antigens, CD34; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D016159:Tumor Suppressor Protein p53